InnovaRx Innova Health Strategies

N85.0

Endometrial hyperplasia

Not billable — category only FY2026 2025-10-01 → 2026-09-30
Exclusions 13 never code together
N85code
Excludes1
  • endometriosis (N80.-)N80.-
  • inflammatory diseases of uterus (N71.-)N71.-
  • noninflammatory disorders of cervix, except malposition (N86-N88)N86-N88
  • polyp of corpus uteri (N84.0)N84.0
  • uterine prolapse (N81.-)N81.-
N00-N99chapter
Excludes2
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • certain infectious and parasitic diseases (A00-B99)A00-B99
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes

No further instructional notes apply.

Index entries leading here filed at null

No alphabetic index entry points at this code.

Alongside this code 9 same parent — N85
Subordinate codes 3
Medications 1

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
no
Code set
FY2026
Parent
N85
Block
N80-N98
Siblings
9
Subordinate
3

Present FY2024–FY2027.